Researchers Submit Patent Application, "Gene Therapy Using Nucleic Acid Constructs Comprising Methyl Cpg Binding Protein 2 (Mecp2) Promoter Sequences", for Approval (USPTO 20230295657).

The nucleic acid construct of claim 49, wherein the at least one synthetic intron comprises the nucleotide sequence of SEQ ID NO: 2 or a nucleotide sequence having at least 90% identity to the nucleotide sequence of the nucleotide sequence of SEQ ID NO: 2. The nucleic acid construct of claim 45, wherein the at least one synthetic intron comprises one or more nucleotide sequences of an MECP2 gene, optionally wherein the at least one synthetic intron comprises one or more intronic sequences of an MECP2 gene and/or one or more non-expressing exonic sequences of an MECP2 gene. The nucleic acid construct of claim 48, wherein the at least one synthetic intron comprises the nucleotide sequence of SEQ ID NO: 2 or a nucleotide sequence having at least 90% identity to the nucleotide sequence of the nucleotide sequence of SEQ ID NO: 2. [Extracted from the article]